KR20150054439A - Composition for Improving, Preventing or Treating Metabolic Diseases comprising Extracts from Borage officinalis - Google Patents

Abstract

The present invention relates to a composition which includes a borage (Borage officinalis) extract and is used for alleviating, preventing, or treating metabolic diseases. The composition includes the borage extract as an active ingredient and is used to alleviate, prevent, or treat the metabolic disease selected from a group including obesity, diabetes, dyslipidemia, fatty liver, and insulin resistance syndrome. Accordingly, the composition can excellently suppress the adipocyte differentiation, reduce the abdominal fat, and improve the serum lipid.

Description

[0001] The present invention relates to a composition for improving, preventing or treating metabolic diseases,

The present invention relates to a composition for improving, preventing or treating metabolic diseases comprising a borage extract.

BACKGROUND ART [0002] Metabolic disease refers to a disease in which various diseases such as diabetes, hypertension, hyperlipidemia, obesity, coronary artery or atherosclerosis are simultaneously caused by chronic metabolic disorders. Reaven (Reaven GM, Diabetes, 1988, 37: 1595 -1607). Metabolic disorders are characterized by insulin resistance, hypertension, and dyslipidemia, most of which are accompanied by overweight or obesity. Metabolic disease is also a risk factor for cardiovascular disease and has been reported to be associated with death from all causes. Unlike type 1 diabetes, the prevalence of metabolic diseases is high in patients with type 2 diabetes mellitus, and it is known that type 2 diabetes mellitus patients have increased mortality when accompanied by metabolic diseases (Bonora E, et al. Diabet Med , 2004, 21: 52-8; Ford ES, Diabetes Care., 2005, 28: 1769-78; Alexander CM, et al. Diabetes, 2003, 52: 1210-1214). In addition, studies on the association of macrovascular and microvascular complications of type 2 diabetes with components of metabolic diseases such as hypertension and dyslipidemia have been published (Mykkanen L, et al. Diabetologia., 1993, 36 : 553-559; Haffner SM, et al. Diabetes, 1992, 41: 715-722).

The most serious problems of metabolic diseases are the occurrence of chronic complications such as diabetic retinopathy, nephropathy, neuropathy, hyperlipidemia, cardiovascular diseases (stroke, angina pectoris, myocardial infarction, peripheral vascular disease) (Wolf SP, Br Med Bull., 1993, 49: 642-652). Most of these chronic complications are irreversible after they have been developed. Until now, there is no way to completely block this process. If the proper treatment is not performed, serious symptoms will be caused and the patient will die. Therefore, for the effective management or treatment of metabolic diseases with complex symptoms, it is ideal to have the effect of treating hypoglycemia, hepatopathy, hyperlipemia, etc. simultaneously with the hypoglycemic effect for maintenance of normal blood glucose. However, And they are separately taking their hypoglycemic agents, hypotensive agents, and cholesterol drugs separately.

Borage officinalis ( Borage officinalis ) is a favorite herb from ancient Greek or Roman times. It is called "cuphorosium" because it drips flowers and leaves into the wine, and when you drink it cleanses all sadness and irritation and makes you feel happy and cheerful . In particular, the leaves contain minerals, calcium, potassium, etc., and are excellent in diuretic, analgesic relief, sweating, cleansing, and skin softening. According to a recent study, the seeds of Borage have "gum marinolenic acid (strength)", which is reported to be effective in acupuncture, eczema, and skin diseases, which are nervous before menstruation. Leaves and flowers are used as a bathing agent to soften and clean the skin, as well as to relax the mind and body, and recently, oil is squeezed from the seeds of barley seeds and used as massage oil and cream for cosmetics.

Numerous papers and patent documents are referenced and cited throughout this specification. The disclosures of the cited papers and patent documents are incorporated herein by reference in their entirety to better understand the state of the art to which the present invention pertains and the content of the present invention.

The present inventors have sought to develop natural products capable of improving, preventing or treating metabolic diseases such as obesity, diabetes, dyslipidemia, fatty liver and insulin resistance syndrome. As a result, Borage The present invention has been accomplished by studying the effect of reducing the differentiation of adipocytes, the effect of reducing the abdominal fat and the effect of improving the blood lipid in the case of treating the extract of P. officinalis .

Other objects and advantages of the present invention will become more apparent from the following detailed description of the invention, claims and drawings.

According to one aspect of the present invention, there is provided a composition for improving, preventing or treating a metabolic disease comprising Borage officinalis extract as an active ingredient.

The present inventors have sought to develop natural products capable of improving, preventing or treating metabolic diseases such as obesity, diabetes, abnormal lipidemia, fatty liver and insulin resistance syndrome. As a result, the effect of reducing the differentiation of adipocytes, the effect of reducing the abdominal fat and the lipid - lowering effect in the case of treating the extract of Borage Extract was confirmed.

When the borage extract used in the composition of the present invention is obtained by treating the borage with an extraction solvent, various extraction solvents may be used. Preferably, a polar solvent or a non-polar solvent can be used. Suitable polar solvents are (i) water, (ii) alcohols (preferably methanol, ethanol, propanol, butanol, n-propanol, iso-propanol, n-butanol, 1-pentanol, Or ethylene glycol), (iii) acetic acid, (iv) dimethyl-formamide (DMFO) and (v) dimethyl sulfoxide (DMSO). Suitable nonpolar solvents are acetone, acetonitrile, ethyl acetate, methyl acetate, fluoroalkane, pentane, hexane, 2,2,4-trimethylpentane, decane, cyclohexane, cyclopentane, diisobutylene, 1- But are not limited to, pentane, 1-chlorobutane, 1-chloropentane, o -xylene, diisopropyl ether, 2- chloropropane, toluene, 1- chloropropane, chlorobenzene, benzene, diethyl ether, diethylsulfide, Methane, 1,2-dichloroethane, aniline, diethylamine, ether, carbon tetrachloride, and THF.

More preferably, the extraction solvent used in the present invention is (a) water, (b) anhydrous or hydrated lower alcohol having 1 to 4 carbon atoms (methanol, ethanol, propanol, butanol, etc.) (E) ethyl acetate, (f) chloroform, (g) butyl acetate, (h) 1,3-butylene glycol, (i) hexane and (j) diethyl ether. . Most preferably, the extract of the present invention is obtained by treating water, ethanol or a combination thereof with a borage.

According to one embodiment of the present invention, the borage extract of the present invention is a borage extract extracted with water, ethanol or a combination thereof.

As used herein, the term " extract " means that it is used in the art as a crude extract as described above, but broadly includes fractions obtained by further fractionating the extract. That is, the borage extract includes not only those obtained by using the above-described extraction solvent, but also those obtained by further applying a purification process thereto. For example, a fraction obtained by passing the above extract through an ultrafiltration membrane having a constant molecular weight cut-off value, and a separation by various chromatography (manufactured for separation according to size, charge, hydrophobicity or affinity) The fraction obtained by the purification method is also included in the extract of the present invention.

The borage extract used in the present invention can be prepared in powder form by an additional process such as vacuum distillation and freeze drying or spray drying.

As used herein, the term "comprising as an active ingredient" means containing an amount sufficient to achieve the efficacy or activity of the following Borage Extracts. The present invention is a composition extracted from a natural plant material, such as a borage. Since the composition does not adversely affect the human body even when administered in an excessive amount, the quantitative upper limit of the composition of the present invention can be selected by a person skilled in the art within a suitable range.

The borage extract of the present invention can improve, prevent or treat a metabolic disease selected from the group consisting of obesity, diabetes, abnormal lipidemia, fatty liver and insulin resistance syndrome.

According to one embodiment of the present invention, the dyslipidemia is hyperlipemia.

According to one embodiment of the present invention, the insulin resistance syndrome includes at least one insulin resistance syndrome selected from the group consisting of obesity caused by insulin resistance, hypertension, arteriosclerosis, hyperlipidemia, hyperinsulinemia and nonalcoholic fatty liver.

The borage extract of the present invention reduces the differentiation of adipocytes. According to one embodiment of the present invention, the borage extract reduces 10-60%, 15-55% or 20-50% differentiation of adipocytes.

The borage extract of the present invention reduces the production of triglycerides. According to one embodiment of the present invention, the barley extract reduces the triglyceride by 20-60%, 30-50% or 35-45%.

The borage extract of the present invention increases the expression of adiponectin. According to one embodiment of the present invention, the barley extract increases mRNA expression of adiponectin by 30-70%, 40-60%, or 45-55% compared to the control.

The borage extract of the present invention reduces the expression of leptin. According to one embodiment of the present invention, the borage extract reduces leptin mRNA expression by 30-70%, 40-60%, or 45-55% compared to the control.

The borage extract of the present invention reduces abdominal fat. According to one embodiment of the invention, the borage extract reduces the production of abdominal fat by 30-70%, 40-60%, or 45-55% compared to the control.

The abdominal fat refers to the fat in the abdominal region between the tissues (e.g., stomach, liver, bowel, kidney, etc.) and visceral fat. Abdominal fat differs from subcutaneous fat under the skin and intramuscular fat located in the skeletal muscle. The fat located in the lower body such as the thighs and hips is subcutaneous, and is not spaced apart from the tissue, while the abdominal fat is usually characterized as viscous and anti-fluid. Abdominal fat is composed of mesenteric, epididymal white adipose tissue (EWAT) and adipose depot of perirenal depot. Abdominal fat is considered to be adipose tissue, while subcutaneous fat is not considered adipose tissue.

The borage extract of the present invention reduces blood total cholesterol, blood triglyceride, blood free fatty acid and blood sugar. According to one embodiment of the present invention, the above borage extract has 10-50%, 20-40% or 25-35%, 45-85%, 55-75% or 60-70%, 30-35% -70%, 40-60%, or 45-55%, and 10-60%, 12-55%, or 14-50%.

Borage extract of the present invention reduces blood pressure rise. According to one embodiment of the present invention, the borage extract reduces 2-20%, 3-18%, or 5-15%.

The composition of the present invention may be provided as a food composition, a functional food composition or a pharmaceutical composition.

The composition of the present invention can be provided as a food composition. When a composition for improving, preventing or treating a metabolic disease selected from the group consisting of obesity, diabetes mellitus, abnormal lipidemia, fatty liver and insulin resistance syndrome comprising the active ingredient of the present Borage Extract is manufactured from a food composition, As well as ingredients normally added in the manufacture of food, as well as proteins, carbohydrates, fats, nutrients, flavoring agents and flavoring agents. Examples of the above-mentioned carbohydrates are monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose, oligosaccharides and the like; And polysaccharides such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavorings such as tau martin and stevia extract (e.g., rebaudioside A and glycyrrhizin) and synthetic flavorings (saccharine, aspartame, etc.) can be used as flavorings. For example, when the food composition of the present invention is prepared as a drink, it may further contain citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, juice, mulberry extract, jujube extract, licorice extract, .

The composition for improving, preventing or treating metabolic diseases selected from the group consisting of obesity, diabetes mellitus, abnormal lipidemia, fatty liver and insulin resistance syndrome comprising the extract of Borage Extract of the present invention as an active ingredient can be prepared from a functional food composition . When the composition of the present invention is prepared with a functional food composition, it includes components that are conventionally added in food production, and includes, for example, proteins, carbohydrates, fats, nutrients, and seasonings. For example, when it is made of a drink, a flavoring agent or a natural carbohydrate may be added as an additional ingredient in addition to the borage extract as an active ingredient. For example, natural carbohydrates include monosaccharides (e.g., glucose, fructose, etc.); Disaccharides (e.g., maltose, sucrose, etc.); oligosaccharide; Polysaccharides (e.g., dextrin, cyclodextrin and the like); And sugar alcohols (e.g., xylitol, sorbitol, erythritol, etc.). Natural flavoring agents (e.g., tau marin, stevia extract, etc.) and synthetic flavoring agents (e.g., saccharin, aspartame, etc.) may be used as flavorings.

The compositions of the present invention may be prepared with pharmaceutical compositions.

According to a preferred embodiment of the present invention, the composition of the present invention comprises (a) the above-mentioned borage extract of the present invention; And (b) a pharmaceutically acceptable carrier. As used herein, the term " pharmaceutically effective amount " means an amount sufficient to achieve efficacy or activity of the above-mentioned barley extract.

When the composition of the present invention is manufactured from a pharmaceutical composition, the pharmaceutical composition of the present invention includes a pharmaceutically acceptable carrier. The pharmaceutically acceptable carriers to be contained in the pharmaceutical composition of the present invention are those conventionally used in the present invention and include lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, But are not limited to, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrups, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. It is not. The pharmaceutical composition of the present invention may further contain a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, etc. in addition to the above components. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington ' s Pharmaceutical Sciences (19th ed., 1995).

The pharmaceutical composition of the present invention can be administered orally or parenterally, and is preferably administered orally.

The appropriate dosage of the pharmaceutical composition of the present invention may vary depending on factors such as the formulation method, administration method, age, body weight, sex, pathological condition, food, administration time, administration route, excretion rate, . Typical dosages of the pharmaceutical compositions of the present invention are in the range of 0.0001-1000 mg / day / kg on an adult basis.

The pharmaceutical composition of the present invention may be formulated into a unit dose form by formulating it using a pharmaceutically acceptable carrier and / or excipient according to a method which can be easily carried out by a person having ordinary skill in the art to which the present invention belongs. Or by intrusion into a multi-dose container. The formulations may be in the form of solutions, suspensions, syrups or emulsions in oils or aqueous media, or in the form of excipients, powders, powders, granules, tablets or capsules, and may additionally contain dispersing or stabilizing agents.

The features and advantages of the present invention are summarized as follows:

(a) The present invention relates to a borage officinalis) extract of obesity containing as an active ingredient, diabetes, or more hypertriglyceridemia (dyslipidemia), fatty liver and insulin resistance syndrome (insulin resistance syndrome) the metabolic disease (the composition for improving, preventing or treating a metabolic disease) is selected from the group consisting of .

(b) The composition of the present invention shows excellent fat cell differentiation inhibiting effect, abdominal fat reducing effect and blood lipid improvement effect.

FIG. 1 shows the results of analysis of cell survival rates at 24 hours, 48 hours and 72 hours after treatment of adipocytes with the extract of Borage.
FIG. 2 shows the result of analysis of trigacylglycerol content after treatment of adipocytes treated with the barley extract.
FIG. 3 shows the results of analysis of the adiponectin mRNA expression level after treatment of adipose cells treated with the extract of Borage.
FIG. 4 shows the results of analysis of leptin mRNA expression after treatment of adipocytes treated with the extract of Borage.
FIG. 5 shows the waist circumference before and after ingesting placebo or barley extract divided into two groups of 25 men and women aged 19 to 60 years old.

Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are only for describing the present invention in more detail and that the scope of the present invention is not limited by these embodiments in accordance with the gist of the present invention .

Example 1: Preparation of Borage Extract

The leaves, flowers and seeds of the barley were mixed and pulverized. Then, 10 times as much volume of purified water was mixed, and the mixture was subjected to hot water extraction for 5 hours at 80 ° C extraction temperature for 6 hours. The extract was filtered, concentrated in vacuo, mixed with 1: 2 of borage and dextrin, and spray-dried to obtain a borage extract.

Example 2: Activity analysis of borage extract

The inhibitory effect of the composition of the present invention on the adipocyte differentiation by inhibiting adipocyte differentiation and the measurement of lipid, lipoprotein and hormone related to intracellular obesity was confirmed.

Inhibitory effect of 3T3-L1 cells on adipocytes

3T3-L1 cells, which are preadipocytes, are widely used for studying the metabolic processes of adipocytes. In the present invention, the anti-obesity effect was greater as the cell differentiation after treatment with the composition in cell culture . 3T3-L1 cells were cultured at 37 ° C in an incubator in which carbon dioxide was supplied at 5% using a culture medium. Cell culture was performed with Dulbecco's Modified Eagle's Media (DMEM) containing 10% fetal bovine serum (FBS) and antibiotics. Cells were washed with phosphate buffered saline (PBS), and incubated with 0.5% trypsin. The cells were desorbed and subcultured. Cells were exchanged for differentiation induction medium containing differentiation inducing substance, insulin (5 μg / ml), dexamethasone (DEX, 0.25 μM) and MTX (1-methyl-3-methylxanthine, 0.5 mM) And induced differentiation into adipocytes. After 3 days of incubation, the cells were cultured in a medium containing only insulin for 2-3 days, and then replaced with a medium in which insulin was removed. During the measurement of glucose in the triglyceride or glucose oxidation, 10-12 days later, the cells were cultured in a medium containing low glucose (5 mM) glucose and treated with the extract of Borage after differentiation induction. The treated cells were counted by MTT assay using cells stuck to 96 wells after 24 hr, 48 hr and 72 hr. Next, the amounts of triacylglycerol, adiponectin and leptin were measured in 3T3-L1 cells differentiated for 10 days after treatment with the extract of Borage Extract.

The results for a significant verification were expressed as mean and standard deviation statistics was used Student's t -test, indicated by p <0.05 considered significant at. The results are shown in Fig. 1 to Fig.

As shown in FIG. 1, when treated with the extract of Borage Extract, the numbers of cells of 21%, 35% and 42% were decreased to 24 hours, 48 hours and 72 hours, respectively, as compared with the control group .

As shown in FIG. 2, when the extract of Borage Extract was treated for 48 hours, the amount of triglyceride in the adipocyte was significantly reduced by 38% compared to the control. As shown in FIG. 3, when mRNA expression of adiponectin was measured after treatment with the extract, the amount of mRNA of adiponectin was increased to about 1.51 times as much as that of the control group when the extract of barley extract was treated for 48 hours .

As shown in FIG. 4, when leptin mRNA expression level was compared with that of the control group, the amount of leptin mRNA was decreased by about 0.49 times as compared to the control group.

Example  3: Determination of the effect of the extract of Borage on the visceral obesity

C57BL / 6J mice were administered with the composition of the present invention to confirm visceral fat reduction effect before and after ingestion.

30 female C57BL / 6J mice (female, 10 weeks old) were fed high fat / high sugar foods (product of Oriental Yeast Co.) for 8 weeks to induce dietary obesity. After that, mice were divided into two groups of 15 rats, and the study was carried out using the normal diet (Oriental Yeast Co.) as the basic formula, and the group treated with the non-treatment group (control group) and the barley extract prepared. In both groups, the mice were allowed to freely eat for 4 weeks, fasted overnight after 4 weeks, and then bled out from the abdominal aorta under ether rumpoon / ketamine anesthesia to slaughter the mice. Next, fat around the uterus and fat around the kidney were extracted and measured. The fat contents of these two parts were combined and recorded as intraperitoneal fat mass. The results are shown in Table 1.

According to the results, it was confirmed that the intraperitoneal fat amount was significantly reduced as well as the overall weight reduction in the mice continuously consuming the barley extract for one month. Therefore, it has been shown that visceral fat accumulated by ingestion of high-fat / high-sugar food is reduced by ingestion of food containing barley extract.

(n = 15, mean ± SD) Food intake (g / day / mouse) Intraperitoneal Fat / Weight (%) Control group 3.13 ± 0.48 1.53 + - 0.21 Borage extract intake group 3.04 ± 0.64 0.79 ± 0.09 *

Example  4: Verification of diabetes preventive effect of barley extract

KK-Ay mouse, an animal model of hereditary obesity and progression to type 2 diabetes, was used to confirm the diabetic prophylactic effect and the lipid metabolism improving effect of the borage extract.

Diabetic mice (female, 8 weeks old) were divided into two groups of 8 mice each, and a control group (non-treated group) and a barley extract-treated group were prepared using normal foods as a basic formula. In all groups, diabetic mice were free to eat for 4 weeks. Borage extracts were added to normal food at a final concentration of 0.3% and used for the study.

During the feeding period, a small amount of blood was collected weekly from the weight of the mouse and the tail vein of the mouse, and the blood glucose was measured using a simple blood glucose testing apparatus.

At the end of the feeding period, the mice were fasted overnight and then lavaged under rumon / ketamine anesthesia to collect blood from the abdominal aorta, and the liver was harvested and measured. Total cholesterol (T-CHO), triglyceride (TG), non-esterified fatty acid (NEFA), glutamic oxaloacetic transaminase (GOT), and glutamic pyruvate transaminase ), LAP (Liver Activator Protein), Cholinesterase (ChoE), total protein (TP-S) and albumin (ALB-S)

Table 2 shows the change in body weight for 4 weeks. In the experimental group treated with the barley extracts compared to the control group, the average weight of the mice was not significantly increased, and a remarkable decrease of 4 g or more was observed from 3 weeks after the intake of the barley extract. The blood glucose data showed a marked decrease in blood glucose compared to the control group 2 weeks after the start of the intake of the borage extract. After 4 weeks of storage for 4 weeks, the blood glucose lowering effect was over 200 ㎎ / ㎗ more than the control group. This means that the extract effectively inhibits blood glucose elevation.

- Mouse weight (g) Blood sugar level (㎎ / ㎗) Control group Borage extract intake group Control group Borage extract intake group Start date 28.3 ± 1.2 29.1 ± 1.7 162 ± 18 159 ± 14 1 week 36.1 ± 1.8 35.3 ± 1.1 401 ± 86 332 + 72 2 weeks 41.3 ± 1.1 37.0 ± 1.6 418 ± 79 321 ± 69 * 3 weeks 44.0 ± 1.4 39.9 ± 0.8 * 462 ± 81 304 ± 61 * 4 weeks 46.7 ± 0.9 41.1 ± 1.2 * 467 ± 95 268 ± 49 *

Table 3 shows the results of liver weight and blood test data. Results showed no statistically significant difference between the control group and those who consumed the barley extract in relation to toxicity such as liver weight, GOT and GPT. This is a result of the fact that the borage extract has no hepatotoxicity. On the other hand, a statistically significant decrease in T-CHO, TG and NEFA was observed in diabetic mice fed the extract of Borage Extract at about 29%, 65% and 49%, respectively, as compared with the control group. This means that the extract of Borage can reduce hyperlipidemia through lipid metabolism improving action.

- Control group Borage extract intake group Liver weight (g / 100g body weight) 4.19 ± 0.82 4.01 + - 0.62 T-CHO (mg / dl) 172 ± 18 121 ± 11 * TG (mg / dl) 137 ± 48 48 ± 17 * NEFA (μEq / L) 3733 + - 704 1905 ± 575 * GOT (lU / L) 104 ± 27 91 ± 18 GPT (lU / L) 35.7 ± 14.7 31.1 ± 12.5 LAP (lU / L) 61.3 ± 9.3 59.3 ± 5.3 ChoE (lU / L) 158 ± 18 159 ± 15 TP-S (g / dl) 4.83 ± 0.36 5.03 + - 0.42 ALB-S (g / dL) 3.01 ± 0.35 2.88 ± 0.53

From the above results, it is shown that the borage extract has both inhibition of blood sugar increase and weight loss as well as improvement of lipid metabolism.

Example  5: Hypertension Prevention Effect of Borage Extract

Spontaneously hypertensive rats (SHR), an animal model of hypertension in which hypertension induced by aging, was used to confirm the antihypertensive efficacy of the extract of Borage Extract.

SHR (male, 6 weeks old) were divided into two groups of 10 per each group, and the experiment was divided into the control group which consumes the normal basic diet and the group which consumes the food containing the borage extract. To induce hypertension, 3 ㎖ / ㎏ / day of propylene glycol was administered to the control group and the borage extract was mixed with propylene glycol at a dosage of 30 ㎎ / 3 ml / kg / day in the borage extract group. All four-week blood pressure lowering effects were confirmed by oral administration. The rest of the meals and water were allowed to eat freely.

Blood pressure was measured in the tail artery using a non-blood vessel automatic blood pressure measuring device on the day immediately preceding the treatment start date and at 7, 14, 21, and 28 days after treatment. Blood pressure measurements were performed before each sample administration. The blood pressure data are shown in Table 4. Before initiation of treatment, blood pressure was 115 mmHg, and all groups were normal. In the control group, blood pressure began to rise at 7 days after treatment and hypertension started to appear. However, when treated with the extract of Borage, the increase of blood pressure was observed to be suppressed unlike the control. On the 14th, 21st and 28th days, the difference was markedly different from the control, and the blood pressure decreased by about 12% Respectively.

- Control group Borage extract intake group Before administration 115 ± 3.1 118 ± 2.7 1 week 137 ± 2.8 126 ± 2.1 * 2 weeks 148 ± 5.1 131 ± 3.6 * 3 weeks 168 ± 4.2 143 ± 6.8 * 4 weeks 167 ± 3.8 147 ± 5.1 *

Example  6: Human test  Weight Control and Obesity

The composition of the present invention was administered to men and women, and body weight control and obesity improvement effect were confirmed through body weight change and body fat measurement before and after ingestion.

Subject and Period

The study group consisted of 50 men and women (22 males and 28 females) aged between 19 and 60 years who were admitted to the study and who were taking placebo and a mixture of this extract (8: 2 mixture ratio) 25 patients were randomly assigned to receive 400 mg / day of placebo or experimental drug for 4 weeks. Subjects were selected to have a body-mass index (BMI) of 23 or more, or a person with an abdominal circumference of 90 cm and a woman of 80 cm or more. Before and after consumption, HDL-cholesterol, triglyceride, and total cholesterol were measured by measuring height, weight, body mass index, waist circumference, blood pressure, pulse, body composition (body fat percentage and fat mass-impedance method) The metabolic risk factor syndrome was assessed by the ingestion.

Body mass  Indices( Body - Mass Index )

Table 5 shows the BMI (Body Mass Index) results of the borage extract-ingested group and the placebo group of the present invention. The results were expressed as mean and standard deviation. Statistical analysis was performed using Student's t- test, and p <0.05 was regarded as significant.

As a result of the test, the BMI of the control group was not significantly different before and after the ingestion, but the BMI of the composition - ing group was significantly reduced to 2.4 kg / m 2 before the intake. This indicates that the composition of the present invention can control or ameliorate obesity or overweight by decreasing the BMI.

BMI (kg / m ² ) Before ingestion After ingestion P value Experimental group (Borage extract) 28.1 ± 0.56 25.73 + - 0.51  0.000 * Placebo 28.9 ± 0.73 27.83 + - 0.62 0.91

Waist circumference

Exhibited a waist circumference of borage extract intake group and the placebo group (Placebo) of the present invention FIG. 5, the result was listed as the average and standard deviation, statistical analysis was used Student's t -test, at p <0.05 Were considered to be significant.

As a result of the test, the waist circumference of the control group was not significantly different before and after the ingestion, but the waist circumference was significantly decreased by about 3.98 ㎝ compared to the intake before the intake of the barley extract. This demonstrates that the composition of the present invention can prevent and improve abdominal fat by reducing waist circumference.

While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the same is by way of illustration and example only and is not to be construed as limiting the scope of the present invention. It is therefore intended that the scope of the invention be defined by the claims appended hereto and their equivalents.

Claims (5)

Borage The present invention relates to a composition for improving, preventing or treating metabolic diseases, which comprises an extract of an officinalis officinalis as an active ingredient.
The composition of claim 1, wherein the metabolic disease is metabolic diseases selected from the group consisting of obesity, diabetes, dyslipidemia, fatty liver and insulin resistance syndrome.
2. The composition of claim 1, wherein the dyslipidemia is hyperlipidemia.
The composition of claim 1, wherein said insulin resistance syndrome comprises at least one insulin resistance syndrome selected from the group consisting of obesity, hypertension, arteriosclerosis, hyperlipidemia, hyperinsulinemia and nonalcoholic fatty liver due to insulin resistance .
The composition of claim 1, wherein the composition is a food composition, a functional food composition, or a pharmaceutical composition.

Images